XDROs in Complex Clinical Infections: An Advanced Course on the Hardest-to-Treat Cases

Learn about infections caused by Gram-negative extensively drug-resistant organisms (XDROs) including molecular epidemiology associated with antimicrobial resistance and approaches to selecting treatment regimens based on the latest data, patient-specific factors and pharmacokinetic/pharmacodynamic considerations through challenging clinical cases led by expert faculty.


  • About extensively drug-resistant organisms (XDROs)
  • Interactive patient cases of infections caused by:
    • Carbapenem-resistant Acinetobacter baumannii
    • Pseudomonas aeruginosa with difficult-to-treat resistance
    • Metallo-β-lactamase–producing Enterobacterales


Date / Time
Event Details


Program Director
Yohei Doi, MD, PhD

Professor of Medicine
Division of Infectious Diseases
University of Pittsburgh School of Medicine
Infectious Diseases Specialist
Division of Infectious Diseases
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Program Director
Emily Heil, PharmD, MS, BCIDP, AAHIVP

Associate Professor
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

Lilian Abbo, MD, FIDSA

Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Miami, Florida

Keith S. Kaye, MD, MPH

Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Goal Statement
The goal of this activity is to improve participants’ competence in selecting appropriate antibiotic regimens for empiric or targeted treatment of complex clinical infections caused by antimicrobial resistant gram-negative pathogens.

Target Audience
This program is intended for physicians (eg, critical care/pulmonologist, infectious disease, internal medicine/hospitalist), pharmacists (critical care, infectious disease), nurses, and other healthcare professionals (eg, NPs/PAs, microbiologists) who provide care for patients with antimicrobial resistant gram-negative infections.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Dfferentiate clinically relevant extensively drug resistant gram-negative organisms (XDROs) including epidemiology, mechanisms of antimicrobial resistance, and virulence factors
  • Compare novel antimicrobial treatment options for patients with antimicrobial resistant gram-negative infections including pharmacokinetics/pharmacodynamics and activity in the setting of key resistance mechanisms
  • Apply latest data and suggested approaches for selection of optimized treatment regimens targeting XDROs in patients with complex clinical infections


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-250-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.